Stuart J Moat1,2, Wioleta M Zelek3, Emily Carne4, Mark J Ponsford4,5, Kathryn Bramhall4, Sara Jones6, Tariq El-Shanawany4, Matt P Wise7, Annette Thomas6, Chloe George8, Christopher Fegan9, Rachael Steven4, Russell Webb4, Ian Weeks10, B Paul Morgan3, Stephen Jolles4. 1. Wales Newborn Screening Laboratory, Department of Medical Biochemistry, Immunology and Toxicology, University Hospital of Wales, Cardiff, Wales, UK. 2. School of Medicine, Cardiff University, Cardiff, Wales, UK. 3. Systems Immunity University Research Institute and Dementia Research Institute, Cardiff University, Cardiff, UK. 4. Immunodeficiency Centre for Wales, University Hospital of Wales, Cardiff, UK. 5. Division of Infection, Inflammation and Immunity, School of Medicine, Cardiff University, Cardiff, UK. 6. Weqas, Cardiff and Vale University Health Board, Cardiff, UK. 7. Adult Critical Care, University Hospital of Wales, Cardiff, UK. 8. Welsh Blood Service, Ely Valley Road, Talbot Green, Pontyclun, UK. 9. Department of Haematology, University Hospital of Wales, Cardiff, Wales, UK. 10. College of Biomedical and Life Sciences, Cardiff University, Cardiff, UK.
Abstract
BACKGROUND: Serological assays for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) have roles in seroepidemiology, convalescent plasma-testing, antibody durability and vaccine studies. Currently, SARS-CoV-2 serology is performed using serum/plasma collected by venepuncture. Dried blood spot (DBS) testing offers significant advantages as it is minimally invasive, avoids venepuncture with specimens being mailed to the laboratory. METHODS: A pathway utilizing a newborn screening laboratory infrastructure was developed using an enzyme-linked immunosorbent assay to detect IgG antibodies against the receptor-binding domain of the SARS-CoV-2 spike protein in DBS specimens. Paired plasma and DBS specimens from SARS-CoV-2 antibody-positive and -negative subjects and polymerase chain reaction positive subjects were tested. DBS specimen stability, effect of blood volume and punch location were also evaluated. RESULTS: DBS specimens from antibody-negative (n = 85) and -positive (n = 35) subjects and polymerase chain reaction positive subjects (n = 11) had a mean (SD; range) optical density (OD) of 0.14 (0.046; 0.03-0.27), 0.98 (0.41; 0.31-1.64) and 1.12 (0.37; 0.49-1.54), respectively. An action value OD >0.28 correctly assigned all cases. The weighted Deming regression for comparison of the DBS and the plasma assay yielded: y = 0.004041 + 1.005x, r = 0.991, Sy/x 0.171, n = 82. Extraction efficiency of antibodies from DBS specimens was >99%. DBS specimens were stable for at least 28 days at ambient room temperature and humidity. CONCLUSIONS: SARS-CoV-2 IgG receptor-binding domain antibodies can be reliably detected in DBS specimens. DBS serological testing offers lower costs than either point of care or serum/plasma assays that require patient travel, phlebotomy and hospital/clinic resources; the development of a DBS assay may be particularly important for resource poor settings.
BACKGROUND: Serological assays for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) have roles in seroepidemiology, convalescent plasma-testing, antibody durability and vaccine studies. Currently, SARS-CoV-2 serology is performed using serum/plasma collected by venepuncture. Dried blood spot (DBS) testing offers significant advantages as it is minimally invasive, avoids venepuncture with specimens being mailed to the laboratory. METHODS: A pathway utilizing a newborn screening laboratory infrastructure was developed using an enzyme-linked immunosorbent assay to detect IgG antibodies against the receptor-binding domain of the SARS-CoV-2 spike protein in DBS specimens. Paired plasma and DBS specimens from SARS-CoV-2 antibody-positive and -negative subjects and polymerase chain reaction positive subjects were tested. DBS specimen stability, effect of blood volume and punch location were also evaluated. RESULTS: DBS specimens from antibody-negative (n = 85) and -positive (n = 35) subjects and polymerase chain reaction positive subjects (n = 11) had a mean (SD; range) optical density (OD) of 0.14 (0.046; 0.03-0.27), 0.98 (0.41; 0.31-1.64) and 1.12 (0.37; 0.49-1.54), respectively. An action value OD >0.28 correctly assigned all cases. The weighted Deming regression for comparison of the DBS and the plasma assay yielded: y = 0.004041 + 1.005x, r = 0.991, Sy/x 0.171, n = 82. Extraction efficiency of antibodies from DBS specimens was >99%. DBS specimens were stable for at least 28 days at ambient room temperature and humidity. CONCLUSIONS: SARS-CoV-2 IgG receptor-binding domain antibodies can be reliably detected in DBS specimens. DBS serological testing offers lower costs than either point of care or serum/plasma assays that require patient travel, phlebotomy and hospital/clinic resources; the development of a DBS assay may be particularly important for resource poor settings.
Authors: Laura Lahdentausta; Anne Kivimäki; Lotta Oksanen; Marika Tallgren; Sampo Oksanen; Enni Sanmark; Aino Salminen; Ahmed Geneid; Mikko Sairanen; Susanna Paju; Kalle Saksela; Pirkko Pussinen; Milla Pietiäinen Journal: Med Microbiol Immunol Date: 2022-06-13 Impact factor: 4.148
Authors: Hannah L Itell; Haidyn Weight; Carolyn S Fish; Jennifer K Logue; Nicholas Franko; Caitlin R Wolf; Denise J McCulloch; Jared Galloway; Frederick A Matsen; Helen Y Chu; Julie Overbaugh Journal: Microbiol Spectr Date: 2021-10-20
Authors: Emma C Tallantyre; Nicola Vickaryous; Stephen Jolles; Ruth Dobson; Valerie Anderson; Aliye Nazli Asardag; David Baker; Jonathan Bestwick; Kath Bramhall; Randy Chance; Nikos Evangelou; Katila George; Gavin Giovannoni; Andrew Godkin; Leanne Grant; Katharine E Harding; Aimee Hibbert; Gillian Ingram; Meleri Jones; Angray S Kang; Samantha Loveless; Stuart J Moat; Neil P Robertson; Klaus Schmierer; Martin J Scurr; Sita Navin Shah; Jessica Simmons; Matthew Upcott; Mark Willis Journal: Ann Neurol Date: 2021-11-17 Impact factor: 11.274
Authors: Martin J Scurr; Wioleta M Zelek; George Lippiatt; Michelle Somerville; Stephanie E A Burnell; Lorenzo Capitani; Kate Davies; Helen Lawton; Thomas Tozer; Tara Rees; Kerry Roberts; Mererid Evans; Amanda Jackson; Charlotte Young; Lucy Fairclough; Paddy Tighe; Mark Wills; Andrew D Westwell; B Paul Morgan; Awen Gallimore; Andrew Godkin Journal: Immunology Date: 2021-12-06 Impact factor: 7.215
Authors: Catherine L Omosule; Justin Conklin; Sohkna Seck; Renée Howell; Karl G Hock; Claire Ballman; James Freeman; Leon Du Toit; Erik Dubberke; Christopher W Farnsworth Journal: Clin Biochem Date: 2022-01-03 Impact factor: 3.281
Authors: Tyler A Jacobson; Jasdeep S Kler; Yeunook Bae; Jiexi Chen; Daniel T Ladror; Ramsunder Iyer; Denise A Nunes; Nathan D Montgomery; Joachim D Pleil; William E Funk Journal: J Expo Sci Environ Epidemiol Date: 2022-08-13 Impact factor: 6.371